Merck Serono Biopharmaceuticals

PharmaVitae Profile

Product Code DAT03273
Publication Date January 2007
Publisher Datamonitor
Product Type Report
Pages 132
ISBN Number not applicable
Change currency
PDF £3,605.00 €4,341 $5,700 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Merck Serono Biopharmaceuticals

PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for Merck Serono in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

  • Benchmark Merck Serono's performance against key rivals in the ethical pharmaceutical sector
  • Learn how the acquisition of Serono has reshaped Merck KGaA's sales outlook to 2011

Contents

  • Chapter 1 Executive Summary
    • Key findings
    • Historical and forecast ethical sales performance
    • Therapeutic strategy
    • Launch and expiry outlook
    • Externalization, geographic and molecule type strategies
    • Externalization strategy
    • Geographic strategy
    • Molecule type strategy
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
  • Chapter 2 Corporate History
    • Key findings
    • Background
    • Key corporate developments
    • M&A history
    • Merck-Serono Biopharmaceuticals
    • Serono vs. Schering AG
    • Current corporate structure
    • Pharmaceuticals
    • Chemicals
    • Current management team
  • Chapter 3 Historical Performance
    • Key findings
    • Introduction
    • Revenue and growth rate analysis, 2002–05
    • Revenue and growth rate vs. peer set
    • Product analysis, 2002–05
    • Growth drivers
    • Growth resistors
    • Operating revenue and cost analysis, 2002–05
    • Operating revenue/cost analysis
  • Chapter 4 Forecast Performance
    • Key findings
    • Introduction
    • Revenue and growth rate, 2005–11
    • Product analysis, 2005–11
    • Growth drivers
    • Growth resistors
    • Therapy area analysis, 2005–11
    • CNS
    • Oncology
    • Therapy area focus
    • Launches and expiries analysis, 2005–11
    • Launch portfolio
    • Core portfolio
    • Expiry portfolio
    • Launch/core/expiry configuration
    • Externalization analysis, 2005–11
    • Geographic analysis, 2005–11
    • Molecule type analysis, 2005–11
  • Chapter 5 Key Products And Competitors
    • Key findings
    • Overview
    • CNS
    • Rebif
    • Novantrone (CNS)
    • Oral cladribine
    • Oncology
    • Erbitux
    • Novantrone (oncology)
    • Women's health
    • Gonal-f
    • Cardiovascular
    • Concor family
    • Autoimmune and inflammatory disorders (AIID)
    • Raptiva
    • R&D pipeline
  • Chapter 6 Appendix
    • IMS vs. company-reported data reconciliation
    • References
    • Abbreviations
    • Exchange rates
  • Table Of Tables
    • Table 1: Merck KGaA's generics portfolio overview ($m), 2005
    • Table 2: Generics: sales forecast ($m), 2005–11
    • Table 3: Merck KGaA Corporate Executive Committee
    • Table 4: Peer set overview
    • Table 5: Operating revenue/cost analysis ($m), 2002–05
    • Table 6: Operating cost ratio analysis (% of total revenues), 2002–05
    • Table 7: Product portfolio overview, sales ($m), 2005–11
    • Table 8: Therapy area overview, sales ($m), 2005–11
    • Table 9: Launch portfolio overview, sales ($m), 2005–11
    • Table 10: Core portfolio overview, sales ($m), 2005–11
    • Table 11: Expiry portfolio overview, sales ($m), 2005–11
    • Table 12: Externally developed portfolio, 2005–11 ($m)
    • Table 13: Molecule type overview, sales ($m), 2005–11
    • Table 14: Key products overview
    • Table 15: Rebif: overview
    • Table 16: Rebif: sales forecast ($m), 2005–11
    • Table 17: Rebif: newsflow
    • Table 18: Novantrone: overview
    • Table 19: Novantrone: sales forecast ($m), 2005–11
    • Table 20: Novantrone: newsflow
    • Table 21: Oral cladribine: overview
    • Table 22: Oral cladribine: sales forecast ($m), 2005–11
    • Table 23: Oral cladribine: newsflow
    • Table 24: Erbitux: overview
    • Table 25: Erbitux: sales forecast ($m), 2005–11
    • Table 26: Product 1: newsflow
    • Table 27: Novantrone (oncology): overview
    • Table 28: Novantrone (oncology): sales forecast ($m), 2005–11
    • Table 29: Novantrone (oncology): newsflow
    • Table 30: Gonal-f: overview
    • Table 31: Gonal-f: sales forecast ($m), 2005–11
    • Table 32: Gonal-f: newsflow
    • Table 33: Concor family: overview
    • Table 34: Concor family: sales forecast ($m), 2005–11
    • Table 35: Product 1: newsflow
    • Table 36: Raptiva: overview
    • Table 37: Raptiva: sales forecast ($m), 2005–11
    • Table 38: Raptiva: newsflow
    • Table 39: Merck KGaA's R&D pipeline (Phase I–registration)
    • Table 40: Merck KGaA's indication broadening pipeline (Phase I–registration)
    • Table 41: Serono's R&D pipeline (Phase I–registration)
    • Table 42: Exchange rates, 2005
  • Table Of Figures
    • Figure 1: Historical and forecast ethical sales performance (% CAGR), Merck-Serono and Mid Pharma peer set
    • Figure 2: Therapeutic focus vs. Mid Pharma peer set (%), 2005
    • Figure 3: Launch, core and expiry, absolute sales growth, 2005–11 (sales as % of 2005 sales), Merck-Serono
    • Figure 4: Launch, core and expiry, absolute sales growth, 2005–11 (sales as % of 2005 sales), peer set
    • Figure 5: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2005
    • Figure 6: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2011
    • Figure 7: SWOT analysis of Merck-Serono
    • Figure 8: Merck-Serono therapy area integration
    • Figure 9: Merck-Serono, sales ($m), 2002–11
    • Figure 10: Merck-Schering, sales ($m), 2002–11
    • Figure 11: Merck-Serono vs. Merck-Schering: externalization, US and biologics dependencies (% ethical sales), 2005
    • Figure 12: Merck-Serono vs. Merck-Schering: externalization, US and biologics dependencies (% ethical sales), 2011
    • Figure 13: Current corporate structure
    • Figure 14: Revenue & growth rate (ethical sales) ($m), 2002–05
    • Figure 15: Ethical revenue ($m) and growth rate (%) vs. peer set, 2002–05
    • Figure 16: Growth drivers/resistor products of historical revenue performance ($m), 2002–05
    • Figure 17: Operating revenue/cost analysis ($m), 2002–05
    • Figure 18: Operating cost ratio analysis (% of total revenues), 2002–05
    • Figure 19: Operating cost ratio vs. peer set, 2002–05
    • Figure 20: Ethical revenue ($m) and growth rate (%), 2005–11
    • Figure 21: Top five products by sales ($m), 2005
    • Figure 22: Top five products by sales ($m), 2011
    • Figure 23: Growth drivers and resistors by product, 2005–11
    • Figure 24: Key strategic products, sales ($m), 2005–11
    • Figure 25: Ethical sales by therapy area ($m), 2005–11
    • Figure 26: Growth drivers and resistors by therapy area (%), 2005–11
    • Figure 27: Ethical sales by therapy area (%), 2005–11
    • Figure 28: Therapy area focus compared with peer set (% total ethical sales), 2005
    • Figure 29: Therapy area focus compared with peer set (% total ethical sales), 2011
    • Figure 30: Launch schedule, sales ($m), 2005–11
    • Figure 31: Core products sales growth ($m), 2005–11
    • Figure 32: Expiry schedule, sales ($m), 2005–11
    • Figure 33: Launch, core and expiry, sales ($m), 2005–11
    • Figure 34: Launch, core and expiry, absolute sales growth, 2005–11 (sales as % of 2005 sales), Merck-Serono
    • Figure 35: Launch, core and expiry, absolute sales growth, 2005–11 (sales as % of 2005 sales), peer set
    • Figure 36: Externalization dependency, sales ($m), 2005–11
    • Figure 37: Growth drivers and resistors, externally vs. internally discovered products, sales ($m), 2005–11
    • Figure 38: Externalization dependency vs. peer set, % total sales, 2005
    • Figure 39: Externalization dependency vs. peer set, % total sales, 2011
    • Figure 40: Geographical sales breakdown ($m), 2005–11
    • Figure 41: Growth drivers and resistors by geography, sales ($m), 2005–11
    • Figure 42: US dependency vs. peer set, % total sales, 2005
    • Figure 43: US dependency vs. peer set, % total sales, 2011
    • Figure 44: Growth drivers and resistors by molecule type, sales ($m), 2005–11
    • Figure 45: Molecule type sales breakdown ($m), 2005–11
    • Figure 46: Biologics dependency vs. peer set, % total sales, 2005
    • Figure 47: Biologics dependency vs. peer set, % total sales, 2011
    • Figure 48: IMS vs. company-reported ethical sales discrepancy ($m), 2005
    • Figure 49: IMS vs. company-reported ethical sales forecast growth rates (%), 2005–11